Department of General, Visceral and Transplantation Surgery, Universitätsklinikum Charité, Campus Virchow Klinikum, Humboldt-Universität, Augustenburger Platz 1, 13353 Berlin, Germany.
J Hepatobiliary Pancreat Sci. 2010 Jul;17(4):509-15. doi: 10.1007/s00534-009-0256-6. Epub 2010 Feb 3.
Intrahepatic cholangiocarcinoma (IHC) is a rare liver malignancy with a rising incidence worldwide. Since no standard treatment has been established so far, the aim of this study was to assess the safety and efficacy of repeated liver resection and/or radiofrequency ablation (RFA) in selected cases with recurrent IHC.
The outcome of 13 patients who had been treated at least once for recurrent IHC by repeated liver resection and/or RFA was retrospectively analyzed. A total of 12 repeated liver resections and 8 radiofrequency ablations were performed in these patients between 2002 and 2008.
After a median follow-up period of 28 months after primary liver resection (12-69 months), seven patients (54%) are still alive and three of these patients (23% of the entire cohort) are regarded as disease-free. The median survival for all patients was 51 months (12-69 months). One- and three-year survival after primary surgery was 92 and 52%, respectively, with an overall complication rate of 7.6%.
According to the present data, repeated liver resection and radiofrequency ablation are feasible in select patients with recurrent IHC. Both procedures can be regarded as safe and might lead to a prolongation of patient survival.
肝内胆管细胞癌（IHC）是一种罕见的肝脏恶性肿瘤，全球发病率呈上升趋势。由于迄今为止尚未确立标准的治疗方法，本研究旨在评估在选定的复发性 IHC 病例中重复肝切除术和/或射频消融（RFA）的安全性和有效性。
回顾性分析了至少接受过一次重复肝切除术和/或 RFA 治疗复发性 IHC 的 13 例患者的结果。这些患者在 2002 年至 2008 年间共接受了 12 次重复肝切除术和 8 次射频消融术。
在初次肝切除后中位随访时间为 28 个月（12-69 个月）后，7 例患者（54%）仍存活，其中 3 例（整个队列的 23%）无疾病。所有患者的中位生存期为 51 个月（12-69 个月）。初次手术后 1 年和 3 年的生存率分别为 92%和 52%，总体并发症发生率为 7.6%。
根据目前的数据，重复肝切除术和射频消融术在选择的复发性 IHC 患者中是可行的。这两种方法都被认为是安全的，可能会延长患者的生存时间。
